Biosimilar biological drugs in the treatment of inflammatory bowel diseases

Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Since 2013, when infliximab originator lost its patent protection, patients with inflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaniewska, Magdalena, Eder, Piotr, Gąsiorowska, Anita, Gonciarz, Maciej, Kierkuś, Jarosław, Małecka-Panas, Ewa, Rydzewska, Grażyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983762/
https://www.ncbi.nlm.nih.gov/pubmed/31988667
http://dx.doi.org/10.5114/pg.2019.90093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983762/
https://www.ncbi.nlm.nih.gov/pubmed/31988667
http://dx.doi.org/10.5114/pg.2019.90093

Ejemplares similares